Rockwell Medical closes at $6.91 ahead of November third-quarter results
Key Facts
Rockwell Medical, listed under the ticker RMTI, closed at $6.91 in the November 2, 2026 session, according to EL7 data. The closing price comes as markets await the company’s third-quarter results, scheduled for November 12. The reported acquisition of Vantive’s global dialysis business could not be confirmed through an open official source or a reliable open source. The acquisition, or details of its scope, therefore cannot be presented as a confirmed development in this coverage. The upcoming results remain the nearest announced milestone for tracking the company’s performance.
Rockwell reported second-quarter 2026 net sales of $17.8 million, up 11% from $16.1 million in the same period of 2025, according to its earnings release. The company attributed sales growth to new customers and purchases by existing customers, linking the increase to rising demand from its customer base and continued buying by established customers. The figures cover the three months ended June 30, 2026, and do not represent the third-quarter results the company will report in November. This performance provides a basis for comparison when the next results are released, giving investors a more recent period of operating activity. No market forecasts for third-quarter results or earnings estimates were available in the information reviewed.
The company ended June 2026 with cash of $24.8 million, after generating $2.1 million in operating cash flow during the second quarter, according to its release. Cash and operating cash flow provide an indication of the resources and liquidity the company disclosed at the end of that period. These figures relate to the second quarter and do not describe the cash position at the end of September or on the date of the upcoming results announcement. In its 2026 annual guidance, Rockwell maintained a range of $70.0 million to $75.0 million for net sales, a gross margin of 18% to 22%, adjusted EBITDA of $1.0 million to $2.0 million, and expectations for positive operating cash flow. These ranges are the company’s estimates for the year, while the November announcement will offer an opportunity to review quarterly performance and whether the company has maintained its annual guidance.
Rockwell says it serves about 300 customers and sells its products in more than 30 international markets, according to its quarterly report filed with the U.S. Securities and Exchange Commission for the period ended June 30, 2026. This footprint gives a picture of the scope of the company’s existing operations, without confirming any additions to its business or markets. The unverified material describes the reported deal as “transformative” in its headline, but no reliable open details are available to attribute that characterization to the company or establish the scope of the alleged transaction. No confirmed information is available on closing terms, regulatory approvals or a timeline for any acquisition. As a result, the deal remains subject to the release of an official announcement whose details can be verified.
Rockwell has set Thursday, November 12, 2026, as the date for announcing its third-quarter results, according to its investor relations page. The release is scheduled for 6:00 a.m. Eastern Time, followed by a live webcast at 8:00 a.m. Eastern Time. The results will provide a view of sales and financial performance for the latest period and allow comparison with second-quarter figures and the announced annual guidance. Any guidance update in the release will also be a key focus for understanding the company’s estimates for the rest of 2026. Until then, the latest available closing price in this information is $6.91 in the November 2 session.